Schalast advised Meliodays Medical GmbH on its pre-seed financing round. The round raised over €800,000. It was led by capacura GmbH. FS Life Science Investment GmbH and other healthcare investors also participated.
Meliodays Medical focuses on hormone-free menstrual pain treatment. With the funds, it will develop “MelioOne,” its new therapy. The therapy uses polymer technology to deliver small doses of pain relief to the uterus. This method avoids systemic side effects. The company plans preclinical testing and owns patents in over 150 countries.
Simone Sabbione, CEO of Meliodays Medical, expressed excitement. She welcomed experienced investors and highlighted their strong support. She noted the recognition of period pain as a major health issue. The funds will help create much-needed solutions.
For detailed information, as well as the picture copyright, please see the law firm´s original article here: Schalast advised Meliodays Medical GmbH on its pre-seed financing round of over EUR 800,000
